OSE Immunotherapeutics Revenue and Competitors

OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I). \n•\tTedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors.\n•\tLusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL.\n•\tOSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors. \n•\tFR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis).\n•\tAnti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024.\n•\tABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation. \n\n4 proprietary drug discovery platforms\n•\tPro-resolutive mAb platform \n•\tMyeloid Checkpoint platform \n•\tBiCKI® Platform\n•\tmRNA Therapeutic platform f